home / stock / ruby / ruby news

RUBY News and Press, Rubius Therapeutics Inc. From 07/02/20

Stock Information
Company Name: Rubius Therapeutics Inc.
Stock Symbol: RUBY
Market: OTC
Website: rubiustx.com
Menu
RUBY RUBY Quote RUBY Short RUBY News RUBY Articles RUBY Message Board
Get RUBY Alerts

News, Short Squeeze, Breakout and More Instantly...
RUBY - Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma

Iveric Bio Goes Ahead with Second Pivotal Phase 3 Study of Zimura Iveric Bio ( ISEE ) announced that it has dosed the first patients for its second pivotal Phase 3 clinical trial GATHER2. The study seeks to evaluate Zimura’s potential for treating patients with geographic atrophy ...
RUBY - Rubius Therapeutics updates on clinical progress of RTX-240 trial

Rubius Therapeutics (NASDAQ: RUBY ) has completed dosing of the first dose-escalation cohort with no observed adverse events to date in the Phase 1/2 clinical trial of RTX-240, an allogeneic cellular therapy for the treatment of patients with relapsed/refractory or locally advanced solid t...

RUBY - Rubius Therapeutics Provides Update on Clinical Trial Progress for its Lead Oncology Product Candidate RTX-240 and Announces Planned Leadership Transition

CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that it has completed dosing of the ...

RUBY - Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic(TM) Oncology Product Candidate for HPV-Positive Cancers, at the American Association of Cancer Research Virtual Annual Meeting II

CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced the presentation of preclinical dat...
RUBY - IPO Update: Generation Bio Proposes IPO Terms

Quick Take Generation Bio ( GBIO ) intends to raise $126 million from the sale of its common stock in a U.S. IPO, per an amended registration statement . The company is a pre clinical developer of genetic treatments for liver and retinal diseases. GBIO is an ultra early stage biopharma ...

RUBY - Rubius Therapeutics (RUBY) Presents At Jefferies Virtual Healthcare Conference - Slideshow

The following slide deck was published by Rubius Therapeutics, Inc. in conjunction with this Read more ...

RUBY - Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity

CAMBRIDGE, Mass. , May 28, 2020 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced that it has further strengthened its executive leadership team with the appointment of Fabrice Chouraqui to the newly created dual role as both CEO-Par...
RUBY - Rubius Therapeutics to Present at Jefferies Virtual 2020 Healthcare Conference

CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that Pablo J. Cagnoni, M.D., chi...

RUBY - Rubius Therapeutics to Present Preclinical Data for RTX-321, a Red Cell Therapeutic(TM) Oncology Product Candidate for HPV-Positive Cancers at the American Association of Cancer Research Annual Meeting

CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the Company plans to present pr...

RUBY - Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic(TM) Oncology Product Candidate for HPV-Positive Cancers, at the American Society of Gene & Cell Therapy 23rd Annual Meeting

CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today presented preclinical data supporting its lead ...
Previous 10 Next 10